Results 221 to 230 of about 427,642 (386)

Clostridium difficile and One Health.

open access: yesClinical Microbiology and Infection, 2020
S. Lim, D. Knight, Thomas V. Riley
semanticscholar   +1 more source

Calcium butyrate efficacy in pediatric irritable bowel syndrome: Randomized placebo‐controlled multiomics‐based clinical trial

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objective Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders, and treatment involves nonpharmacological and pharmacological therapies, even if there is no optimal therapy. This randomized, placebo‐controlled, double‐blind trial aimed to evaluate the efficacy of calcium butyrate supplementation in ...
Fernanda Cristofori   +11 more
wiley   +1 more source

GROWTH REQUIREMENTS OF CLOSTRIDIUM TETANI

open access: hybrid, 1941
J. Howard Mueller, Pauline A. Miller
openalex   +1 more source

Have we hit the JAK‐pot? Success of selective JAK 1 inhibitor following failure of pan‐JAK inhibitor in refractory pediatric ulcerative colitis

open access: yesJPGN Reports, EarlyView.
Abstract The treatment options available for pediatric ulcerative colitis (UC) are challenging due to few with Federal Drug Administration approval. Newer medications approved for adults include additional biologics with differing mechanisms of action and small molecule drugs, such as Janus kinase (JAK) inhibitors.
Jessica A. Black, Brad Pasternak
wiley   +1 more source

Gut microbial utilization of the alternative sweetener, D-allulose, via AlsE. [PDF]

open access: yesCommun Biol
Minabou Ndjite G   +5 more
europepmc   +1 more source

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection

open access: yesNew England Journal of Medicine, 2017
M. Wilcox   +20 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy